echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Evaluation of the effect of mRNA-1273 vaccine in adolescents aged 12-17

    NEJM: Evaluation of the effect of mRNA-1273 vaccine in adolescents aged 12-17

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The global new crown pneumonia epidemic is still continuing
    .
    According to statistics, the incidence of new coronary pneumonia in adolescents between the ages of 12 and 17 is about 900 per 100,000 population.


    Although children with Covid-19 usually have milder symptoms than adults, it can also lead to hospitalization.


    The new crown pneumonia children Recently researchers examined the safety, mRNA-1273 vaccine in 12-17-year-olds in the population of immune immunogenicity and efficacy


    This study is a phase II-III clinical study.


    Healthy 12-17-year-old adolescents received 2 doses of mRNA-1273 vaccine (100μg each time) or placebo, with an interval of 28 days


    Prevent infection

    A total of 3732 adolescents participated in the study, of which 2489 were vaccinated and 1243 received a placebo
    .
    In the vaccine group, the most common adverse events were pain at the injection site (93.


    1% after the first vaccination, 92.


    Adverse events in adolescents after mRNA-1273 vaccination

    Adverse events in adolescents after mRNA-1273 vaccination Adverse events in adolescents after mRNA-1273 vaccination

    Compared with young people, the geometric mean titer ratio of virus neutralizing antibody titers after vaccination in young people is 1.
    08, and the absolute difference in serological response is 0.
    2%, reaching non-inferiority
    .
    14 days after completing the second dose of vaccination, there were no cases of new coronary pneumonia infection in the vaccine group and 4 cases in the placebo group


    .


    Compared with young people, the geometric mean titer ratio of virus neutralizing antibody titers after vaccination in young people is 1.


    Protective efficacy of mRNA-1273 vaccine

    The protective effect of mRNA-1273 vaccine The protective effect of mRNA-1273 vaccine

    Studies believe that the mRNA-1273 vaccine is safe in adolescents aged 12-17, and its immune response induction effect is equivalent to that of adults, and it can effectively prevent new coronary pneumonia


    .


    The mRNA-1273 vaccine is safe in adolescents aged 12-17.


    Original source:

    Kashif Ali et al.


    Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.